Sofituzumab vedotin
Product Specifications
UNSPSC Description
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].
Target Antigen
Antibody-Drug Conjugates (ADCs)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sofituzumab-vedotin.html
Purity
98.72
Solubility
H2O
Smiles
[Sofituzumab vedotin]
Molecular Weight
144000 (average)
References & Citations
[1]Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223.|[2]Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130.|[3]Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99593/Sofituzumab-vedotin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99593/Sofituzumab-vedotin-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
1418200-58-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
